Anthony J Rothschild

Summary

Publications

  1. doi request reprint The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder
    Anthony J Rothschild
    Department of Psychiatry, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA, USA Electronic address
    Compr Psychiatry 55:1-10. 2014
  2. pmc Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II
    Alastair J Flint
    Department of Psychiatry, University of Toronto, Toronto, Canada
    BMC Psychiatry 13:38. 2013
  3. pmc Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study
    Anthony J Rothschild
    University of Massachusetts Medical School, Worcester, MA, USA
    Psychopharmacol Bull 42:5-20. 2009
  4. pmc Challenges in the treatment of major depressive disorder with psychotic features
    Anthony J Rothschild
    University of Massachusetts Medical School and UMass Memorial Healthcare, Worcester, MA, USA
    Schizophr Bull 39:787-96. 2013
  5. pmc A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)
    Barnett S Meyers
    Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester Division, White Plains, New York 10605, USA
    Arch Gen Psychiatry 66:838-47. 2009
  6. pmc Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder
    Boadie W Dunlop
    Department of Psychiatry, Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30306, USA
    J Psychiatr Res 45:96-103. 2011
  7. doi request reprint Weight gain during olanzapine treatment for psychotic depression: effects of dose and age
    Eric Smith
    Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Int Clin Psychopharmacol 23:130-7. 2008
  8. pmc Correlation between patient and clinician assessments of depression severity in the PREVENT study
    Boadie W Dunlop
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA
    Psychiatry Res 177:177-83. 2010
  9. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
  10. ncbi request reprint Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features
    Carmen Andreescu
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Psychiatry 68:194-200. 2007

Collaborators

Detail Information

Publications24

  1. doi request reprint The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder
    Anthony J Rothschild
    Department of Psychiatry, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA, USA Electronic address
    Compr Psychiatry 55:1-10. 2014
    ....
  2. pmc Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II
    Alastair J Flint
    Department of Psychiatry, University of Toronto, Toronto, Canada
    BMC Psychiatry 13:38. 2013
    ..On the other hand, premature discontinuation of antipsychotic medication has the potential risk of early relapse of a severe disorder...
  3. pmc Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study
    Anthony J Rothschild
    University of Massachusetts Medical School, Worcester, MA, USA
    Psychopharmacol Bull 42:5-20. 2009
    ..Antidepressant tachyphylaxis describes the return of apathetic depressive symptoms, such as fatigue and decreased motivation, despite continued use of a previously effective treatment...
  4. pmc Challenges in the treatment of major depressive disorder with psychotic features
    Anthony J Rothschild
    University of Massachusetts Medical School and UMass Memorial Healthcare, Worcester, MA, USA
    Schizophr Bull 39:787-96. 2013
    ..Little is known regarding the optimal treatment of a patient with bipolar disorder who has an episode of psychotic depression or the clinical characteristics of responders to medication treatments vs ECT treatments...
  5. pmc A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)
    Barnett S Meyers
    Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester Division, White Plains, New York 10605, USA
    Arch Gen Psychiatry 66:838-47. 2009
    ..Evidence for the efficacy of combination pharmacotherapy has been limited and without positive trials in geriatric patients with major depression (MD) with psychotic features...
  6. pmc Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder
    Boadie W Dunlop
    Department of Psychiatry, Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30306, USA
    J Psychiatr Res 45:96-103. 2011
    ..Poor agreement between patient- and clinician-ratings of depression severity is primarily a state phenomenon, although it is trait-like for some patients...
  7. doi request reprint Weight gain during olanzapine treatment for psychotic depression: effects of dose and age
    Eric Smith
    Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Int Clin Psychopharmacol 23:130-7. 2008
    ..05 kg). Cumulative olanzapine dose was also significantly associated with weight gain (P<0.0001). Approximately 60% of completers of the 12-week trial experienced clinically significant weight gain (> or =7% of baseline weight)...
  8. pmc Correlation between patient and clinician assessments of depression severity in the PREVENT study
    Boadie W Dunlop
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA
    Psychiatry Res 177:177-83. 2010
    ..This study analyzed agreement between commonly used depression rating scales in the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) trial...
  9. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  10. ncbi request reprint Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features
    Carmen Andreescu
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Psychiatry 68:194-200. 2007
    ..We assessed the extent to which the pharmacotherapy received by patients with MD-Psy under usual care conforms to these recommendations...
  11. ncbi request reprint Missed diagnosis of psychotic depression at 4 academic medical centers
    Anthony J Rothschild
    Department of Psychiatry, University of Massachusetts Medical School, and UMass Memorial Healthcare, Worcester, MA 01605, USA
    J Clin Psychiatry 69:1293-6. 2008
    ..Major depressive disorder with psychotic features (psychotic depression), though occurring relatively frequently in the general population, is a commonly missed psychiatric diagnosis...
  12. pmc Progression of female reproductive stages associated with bipolar illness exacerbation
    Wendy K Marsh
    Department of Psychiatry, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA 01605, USA
    Bipolar Disord 14:515-26. 2012
    ..Late perimenopause and early postmenopause confer an increased risk of depression in the population, yet bipolar disorder mood course during these times remains unclear...
  13. ncbi request reprint A delusion assessment scale for psychotic major depression: Reliability, validity, and utility
    Barnett S Meyers
    Department of Psychiatry, Weill Medical College of Cornell University, New York Presbyterian Hospital Westchester Division, West Chester, New York 10605, USA
    Biol Psychiatry 60:1336-42. 2006
    ..The development and assessment of the Delusional Assessment Scale (DAS) are described...
  14. doi request reprint Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic
    Anna Glezer
    Massachusetts General Hospital McLean Hospital Psychiatry Residency Training Program, University of Massachusetts Medical School, Boston, MA 02114, USA
    J Affect Disord 117:18-23. 2009
    ..Therefore, it is important to understand the effects of polypharmacy on efficacy of treatment as well as whether polypharmacy is instituted after appropriate initial monotherapy trials. This study attempts to answer these questions...
  15. ncbi request reprint Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account
    Søren D Ostergaard
    Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aalborg University Hospital, Mølleparkvej 10, DK 9000 Aalborg, Denmark Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Electronic address
    J Affect Disord 160:68-73. 2014
    ....
  16. ncbi request reprint The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity
    Anthony J Rothschild
    Department of Psychiatry, University of Massachusetts Medical School and UMassMemorial Healthcare, Inc, Worcester, MA 01605, USA
    Compr Psychiatry 49:508-13. 2008
    ..To address this problem, the development and assessment of the Rothschild Scale for Antidepressant Tachyphylaxis (RSAT) are described...
  17. doi request reprint Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial
    Eric G Smith
    Department of Psychiatry, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA 01655
    J Clin Psychiatry 74:966-73. 2013
    ..We conducted a randomized, double-blind, placebo-controlled trial of the NMDA antagonist memantine as an augmentation treatment for patients with DSM-IV major depressive disorder...
  18. ncbi request reprint A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features
    Anthony J Rothschild
    Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01605, USA
    J Clin Psychopharmacol 24:365-73. 2004
    ....
  19. doi request reprint Relationships between multiple sclerosis and depression
    Nancy Byatt
    Dept of Psychosomatic Medicine Emergency Mental Health, UMass Memorial Health Care, the Center for Psychopharmacologic Research and Treatment, University of Massachusetts Medical School, Worcester, MA
    J Neuropsychiatry Clin Neurosci 23:198-200. 2011
    ..Lifetime prevalence of MDD was 59%; 14% of subjects reported MDD as a prodrome to MS, and 10% reported a resulting delay in MS diagnosis...
  20. ncbi request reprint How long should patients with psychotic depression stay on the antipsychotic medication?
    Anthony J Rothschild
    Department of Psychiatry, University of Massachusetts Medical School, Worcester, 01605, USA
    J Clin Psychiatry 64:390-6. 2003
    ..Despite the frequent relapse and recurrence in major depression with psychotic features, there are few studies of the efficacy of continuation and maintenance treatments...
  21. ncbi request reprint Psychiatric outcomes following medical and surgical abortion
    Dorothy Sit
    Department of Psychiatry, University of Pittsburgh School of Medicine, PA 15213, USA
    Hum Reprod 22:878-84. 2007
    ..The objectives were to determine post-abortion depression risk, evaluate risk factors for post-abortion depression and to explore the relationship between cortisol and depression...
  22. ncbi request reprint Challenges in the treatment of depression with psychotic features
    Anthony J Rothschild
    Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Biol Psychiatry 53:680-90. 2003
    ..Many questions regarding the acute and long-term treatment of MDpsy remain for future studies to address...
  23. doi request reprint Manic episode after total abdominal hysterectomy with bilateral salpingo-oophorectomy: case report
    Wendy K Marsh
    Department of Psychiatry, University of Massachusetts School of Medicine, Worcester, MA 01605, USA
    Menopause 19:476-8. 2012
    ..Mood state in women with bipolar disorder during the rapid decline in reproductive hormones resulting from surgical menopause has not been reported...
  24. doi request reprint Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
    Anthony J Rothschild
    University of Massachusetts Medical School and UMass Memorial Healthcare, Worcester, MA, United States
    Eur Neuropsychopharmacol 22:858-66. 2012
    ..Most AEs were mild to moderate in severity. In conclusion, in this trial, vortioxetine did not improve symptoms of GAD (compared with placebo) over 8 weeks of treatment. Vortioxetine was well tolerated in this study...